obesity drug news today glp-1 oct 27 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Medicare $50 GLP-1 Weight Loss
Description
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity
The Moro orange, known for its deep pigmentation due to a high concentration of anthocyanins, is thought to have originated in Sicily in the early 1800s
GLP-1 RAs have gained attention for treating obesity and type 2 diabetes (T2DM), largely due to their ability to reduce gastric motility
Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma
Mounjaro is a newer option that targets two hormones and can be discussed with healthcare providers for suitable treatment plans
A dual GIP/GLP-1 agonist studied in metabolic research
